Nomad Power Solutions, Inc. (NMAD) Stock Price & Analysis
Nomad Power Solutions, Inc. (NMAD) rose 10.26% to USD 4.03 as of September 8, 2026 at 05:49 UTC, according to Nexqual real-time market data.
NMAD last closed at USD 4.03; the session ranged USD 3.51–4.05 on volume of 322,404 shares. Market capitalization is —, with a 52-week range of USD 2.36–8.38 (NCM). Source: Nexqual, September 8, 2026 at 05:49 UTC.
Key Statistics (as of September 8, 2026 at 05:49 UTC)
| Price | USD 4.03 |
|---|---|
| Change | ▲ 10.26% (up) |
| Previous Close | USD 4.03 |
| Open | USD 4.03 |
| Day Range | USD 3.51 – 4.05 |
| 52-Week Range | USD 2.36 – 8.38 |
| Volume | 322,404 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (NMAD)
Nexqual's technical model rates NMAD "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:49 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.09 (neutral) |
| vs SMA50 | Below (USD 4.93) |
| MACD | -0.21 (negative) |
From Nomad Power Solutions, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Liora's proprietary technology, known as LiGHT System (Linac for Image Guided Hadron Therapy), has significant advantages over currently available technologies for treating tumors with proton therapy.
- The Company's ability to stop third parties from making, using, selling, offering to sell, or importing our technology may depend on the extent to which the Company has rights under valid and enforceable licenses, patents, or trade secrets that cover these activities.
Partnerships
- We completed the enrollment of the first 21 patients in Q4, 2025 and expect patient 22 to be enrolled in Q1 2026.   Netherlands Cancer Institute Clinical Trial   Effective June 10, 2024, we entered into a Clinical Trial Agreement with the Netherlands Cancer Institute ("NKI") to conduct a Phase 1b clinical trial of the Company's protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F.
- Because of the large footprint and high price of many proton therapy systems, there is increasing demand for the development of smaller, more compact proton therapy systems.     Facilities   Liora's equipment and operations are located in part of the Tower at Daresbury Laboratory, Daresbury Cheshire, United Kingdom, pursuant to a lease agreement with the United Kingdom Research and Innovation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.46 | ▲ 2.93% |
| ABVC | ABVC Biopharma, Inc. | USD 0.96 | ▲ 10.98% |
| BBLG | Bone Biologics Corp | USD 0.57 | ▲ 3.27% |
| PALI | Palisade Bio, Inc. | USD 2.09 | ▲ 5.03% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.55 | ▼ 1.54% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:49 UTC. This page is informational and not investment advice.